Govt Expands Central Drugs Laboratory at CCS‑NIAH to Test 42 Veterinary Vaccines – Boosting Regulatory Capacity

Overview The Ministry of Health and Family Welfare has issued a Gazette notification (G.S.R. 65(E), dated 28 January 2026 ) amending the Drugs Rules 1945 . The amendment expands the role of the CDL at the CCS‑NIAH , Baghpat, to include testing of 42 veterinary vaccines . This move strengthens India’s veterinary biological testing ecosystem. Key Developments Notification issued under the Drugs and Cosmetics Act 1940 (G.S.R. 65(E), 28 Jan 2026). Testing scope at CCS‑NIAH increased from 2 to 42 vaccines. Vaccines now covered include those for canine distemper, canine coronavirus, duck plague, fowl pox, salmonella, tetanus and other livestock diseases. Enhanced capacity aims to speed up import clearance and reduce testing timelines for manufacturers. Official notification available on the e‑Gazette (https://egazette.gov.in/WriteReadData/2026/273682.pdf). Important Facts India is among the world’s leading producers of veterinary vaccines. Prior to the amendment, CCS‑NIAH could test only two vaccines. The new mandate now allows testing of 42 vaccines, covering diseases that affect dogs, horses, poultry and other livestock. The expanded testing facility is expected to improve the ease of import, shorten regulatory clearance time, and reinforce the national quality‑assurance system for animal health products. UPSC Relevance This development touches upon several UPSC syllabus areas: Governance & Policy (role of the Ministry of Health, regulatory framework under the Drugs and Cosmetics Act ), Agriculture & Animal Husbandry (importance of veterinary vaccines for livestock productivity and food security), and Economic Development (boost to the domestic vaccine industry and potential export opportunities). Understanding the regulatory process helps answer questions on public health infrastructure and animal husbandry reforms. Way Forward To fully leverage the expanded capacity, the government should: Facilitate faster approval of new vaccine candidates by streamlining laboratory workflows. Promote collaboration between research institutes, vaccine manufacturers, and state veterinary departments. Ensure continuous up‑skilling of laboratory personnel to handle the broader test portfolio. Monitor impact on import timelines and domestic vaccine availability through periodic reviews. These steps will help maintain high standards of animal health, support farmer livelihoods, and reinforce India’s position in the global veterinary vaccine market.